Multiplikator Forward P/S BeiGene Corp (ONC)
An international network of clinics and unique molecules create barriers to entry for competitors, while the expansion of Brukinsa drives current growth. The projected P/S multiple smooths out market noise, and its current value is 5.30. The integration of Asian research with the Western market transforms BeiGene Ltd (ONC) into a key hub for blood cancer therapy, bridging the gap between science and commerce.
ONC (BeiGene Oncology): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- statistik nilai buku emiten:
- rincian utang lan likuiditas:
Total Utang marang Modal BeiGene Ltd|ONC - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas BeiGene Ltd|ONC - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku BeiGene Oncology|ONC - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan BeiGene|Rasio cepet beigene.com
- rincian asil keuangan lan kelipatan valuasi:
ONC - Bathi perusahaan|Bathi sing dikarepake BeiGene Ltd|ONC - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep BeiGene Corp|ONC - Rasio P/E diaturake wutah|Pangali EV/EBITDA BeiGene Oncology|ONC - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) BeiGene|ONC - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan beigene.com|ONC - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep BeiGene Ltd
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:ONC (BeiGene)
Innovative drugs from BeiGene Ltd (ONC) secure the company's leadership in oncology, yet geopolitical friction between the US and China creates uncertainty regarding future sales. By analyzing the forward P/S ratio, an investor assesses current capitalization relative to expected revenue for the coming year. This indicator helps determine the asset's level of overboughtness and evaluate market expectations in light of regulatory risks across Western markets.
Karo sapa BeiGene Ltd saingan
Multiplikator Forward P/S HALO (Halozyme)|Rasio kapitalisasi marang dodolan sing dikarepake Revolution Medicines Inc (RVMD)|Ascentage - Multiplikator Forward P/S|Prakiraan rega marang pendapatan CG Oncology Therapeutics (CGON)|URGN: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep bicara.com (BCAX)|Rasio rega marang prakiraan pendapatan Personalis|Kapitalisasi marang prakiraan pendapatan ERAS (Erasca Inc)|Multiplikator Forward P/S DCTH|YMAB - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Aura Biosciences, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CADL|ARAY - Rasio rega marang prakiraan pendapatan|SLS: Rasio rega marang prakiraan pendapatan|ACTU (Actuate Therapeutics, Inc) - Multiplikator forward rega marang pendapatan|CTOR: Rasio rega marang pendapatan sing dikarepake|HURA (TuHURA Biosciences Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan TARA (protaratx.com)|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|WHWK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan TScan Therapeutics, Inc. TCRX|CSBR: Kapitalisasi marang prakiraan pendapatan|XBiotech USA - Multiplikator Forward P/S|CEL-SCI Corporation (CVM) - Multiplikator forward rega marang pendapatan|OSTX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Adlai Nortye Limited|Rasio rega marang prakiraan pendapatan Veru Inc. (VERU)|tempesttx.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S XLO (Xilio Therapeutics)|RENB - Multiplikator forward rega marang pendapatan|Mural Bio - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Rasio rega marang prakiraan pendapatan|CytoMed Therapeutics Limited - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CRIS|APLM: Rega forward marang dodolan|Multiplikator Forward P/S THAR|Multiplikator forward rega marang pendapatan advanbiomed.com ADVB|Genprex, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Calidi Biotherapeutics Inc. CLDI|SBFM - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan XBIO (Xenetic Biosciences)|SLRX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan BGNE|Multiplikator Forward P/S CKPT|ELEV - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S ICAD (iCAD)|Rasio kapitalisasi marang dodolan sing dikarepake Ikena Oncology Inc. (IKNA)|Notable Labs, Ltd. - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Viracta Therapeutics (VIRX)|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
